Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CyPA CRISPR Activation Plasmid (h): sc-418155-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CyPA CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CyPA CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CyPA CRISPR Activation Plasmid (h) and CyPA CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PPIA transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CyPA Antibody (6-YD13): sc-134310
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CyPA CRISPR Activation Plasmid (h) | sc-418155-ACT | 20 µg | $397.00 | |||
CyPA CRISPR Activation Plasmid (h2) | sc-418155-ACT-2 | 20 µg | $397.00 |
Human PPIA encodes cyclophilin A (CyPA), a ubiquitous peptidyl-prolyl cis-trans isomerase that accelerates protein folding and conformational switching in the cytosol and nucleus. CyPA participates in proteostasis, chaperone networks, and stress-responsive signaling, and its interaction with target proteins can influence transcriptional programs, apoptosis, and inflammatory responses. The PPIA/CyPA axis has been linked to modulation of immune signaling and host–pathogen interactions, and altered expression or activity is frequently examined in cancer biology, cardiovascular inflammation, and neuroinflammatory contexts. As a cellular hub protein, CyPA is commonly used to probe pathways governing protein trafficking, redox and stress adaptation, and signaling complex assembly.
CyPA CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PPIA expression without altering the underlying DNA sequence.
CyPA CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PPIA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PPIA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CyPA expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PPIA locus and enabling the study of CyPA-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CyPA pathway restoration in tumor cells with silenced or reduced PPIA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.